The company will use the proceeds to test its gene therapy XC001 in two Phase II studies involving patients with cardiovascular disease.

Continuing significant advancements in the field of xenotransplantation, surgeon-scientists from the University of Maryland ...

After a heart attack, humans lose millions of heart muscle cells that cannot regrow, often leading to heart failure where the ...

The company is trying to develop a one-time treatment for forms of heart disease that afflict more than 1 million people in ...

The new name draws from the company’s nearly two decades of work in ryanodine receptor (RyR) biology, which it has used to ...

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving ...

Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025Cyprium is eligible to receive royalties and up to $129 ...

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

Researchers have discovered that the protein Hmga1, found in zebrafish, can repair damaged mouse hearts by reactivating ...